Clinical Trial Update: Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Tc99m-Maraciclatide scintigraphy in adults with diabetes mellitus and heart failure with preserved ejection fraction; the study was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Tc99m-Maraciclatide (Maraciclatide)

Snippet

Sponsor: GE Healthcare | Conditions: Diabetes Mellitus, Heart Failure | Phase 2 | Status: TERMINATED | Results posted: 2014-02-04